Appili Therapeutics Stock Performance
| APLI Stock | CAD 0.03 0.01 14.29% |
The firm shows a Beta (market volatility) of 2.36, which signifies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Appili Therapeutics will likely underperform. Appili Therapeutics right now shows a risk of 8.53%. Please confirm Appili Therapeutics total risk alpha, treynor ratio, and the relationship between the jensen alpha and sortino ratio , to decide if Appili Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Insignificant
Over the last 90 days Appili Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Appili Therapeutics is not utilizing all of its potentials. The recent stock price disarray, may contribute to short-term losses for the investors. ...more
1 | Aditxt receives positive FDA feedback on ATI-1801 development By Investing.com - Investing.com UK | 10/31/2024 |
2 | Appili Therapeutics Moves Forward with Aditxt Acquisition - TipRanks | 11/19/2024 |
| Begin Period Cash Flow | 2.5 M |
Appili |
Appili Therapeutics Relative Risk vs. Return Landscape
If you would invest 3.50 in Appili Therapeutics on October 11, 2024 and sell it today you would lose (0.50) from holding Appili Therapeutics or give up 14.29% of portfolio value over 90 days. Appili Therapeutics is generating 0.0992% of daily returns and assumes 8.53% volatility on return distribution over the 90 days horizon. Simply put, 75% of stocks are less volatile than Appili, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Appili Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Appili Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Appili Therapeutics, and traders can use it to determine the average amount a Appili Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0116
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | APLI |
| Negative Returns |
Estimated Market Risk
| 8.53 actual daily | 75 75% of assets are less volatile |
Expected Return
| 0.1 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.01 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Appili Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Appili Therapeutics by adding Appili Therapeutics to a well-diversified portfolio.
Appili Therapeutics Fundamentals Growth
Appili Stock prices reflect investors' perceptions of the future prospects and financial health of Appili Therapeutics, and Appili Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Appili Stock performance.
| Return On Equity | -9.39 | ||||
| Return On Asset | -2.44 | ||||
| Operating Margin | (10.40) % | ||||
| Current Valuation | 14 M | ||||
| Shares Outstanding | 121.27 M | ||||
| Price To Book | 1.40 X | ||||
| Price To Sales | 5.13 X | ||||
| Revenue | 827.41 K | ||||
| Gross Profit | 1.39 M | ||||
| EBITDA | (8.01 M) | ||||
| Net Income | (3.78 M) | ||||
| Cash And Equivalents | 5.55 M | ||||
| Cash Per Share | 0.05 X | ||||
| Total Debt | 8.18 M | ||||
| Current Ratio | 1.99 X | ||||
| Book Value Per Share | (0.09) X | ||||
| Cash Flow From Operations | (2.54 M) | ||||
| Earnings Per Share | (0.03) X | ||||
| Market Capitalization | 4.24 M | ||||
| Total Asset | 1.49 M | ||||
| Retained Earnings | (69.09 M) | ||||
| Working Capital | (10.08 M) | ||||
About Appili Therapeutics Performance
By examining Appili Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Appili Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Appili Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 2.1 K | 2.2 K | |
| Return On Tangible Assets | (2.92) | (3.06) | |
| Return On Capital Employed | 0.92 | 0.97 | |
| Return On Assets | (2.92) | (3.06) | |
| Return On Equity | 0.31 | 0.45 |
Things to note about Appili Therapeutics performance evaluation
Checking the ongoing alerts about Appili Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Appili Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Appili Therapeutics had very high historical volatility over the last 90 days | |
| Appili Therapeutics has some characteristics of a very speculative penny stock | |
| Appili Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 827.41 K. Net Loss for the year was (3.78 M) with profit before overhead, payroll, taxes, and interest of 1.39 M. | |
| Appili Therapeutics has accumulated about 5.55 M in cash with (2.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.05, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Appili Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Appili Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Appili Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Appili Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Appili Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Appili Therapeutics' stock. These opinions can provide insight into Appili Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Appili Stock
Appili Therapeutics financial ratios help investors to determine whether Appili Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Appili with respect to the benefits of owning Appili Therapeutics security.